We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App




Multiplex Real-Time PCR Assay Simultaneously Detects and Identifies 9 Parasitic Gastrointestinal Pathogens

By LabMedica International staff writers
Posted on 12 May 2023
Print article
Image: The Allplex GI-Helminth(I) Assay is the first marketed multiplex PCR for helminth diagnosis (Photo courtesy of Seegene)
Image: The Allplex GI-Helminth(I) Assay is the first marketed multiplex PCR for helminth diagnosis (Photo courtesy of Seegene)

The field of parasitology has seen a growing interest in molecular biology. Molecular tools have been extensively used in disciplines such as bacteriology and virology, but the identification of intestinal parasites has been hampered by technical hurdles. Specifically, working with stool samples can be problematic due to the high presence of inhibitors that can disrupt PCR reactions. A novel multiplex PCR assay that allows for the reliable and efficient detection of numerous parasites in a single testing run marks a significant milestone in the field of parasitology.

Seegene, Inc.’s (Seoul, Korea) Allplex GI-Helminth(I) Assay is the first commercially available multiplex PCR assay for the identification of helminths in human stool samples. The assay makes it possible to simultaneously detect and identify nine gastrointestinal parasitic pathogens using real-time PCR. The Allplex GI-Helminth(I) Assay can detect one protozoan and eight helminths, all of which are highly pathogenic parasites. The assay, based on Seegene’s exclusive MuDT technology, provides multiple Ct values for each pathogen in a single channel using real-time PCR instrumentation.

By enabling the simultaneous detection of full range of common intestinal parasites, the informative assay assists in appropriate treatment and management for co-infection. In addition, accurate test results allow for quick and proper treatment. The assay offers a convenient workflow using Seegene’s automated One platform, along with automated data interpretation and LIS interlocking with Seegene Viewer.

Related Links:
Seegene, Inc.

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.